Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon May 06, 2024 2:11pm
203 Views
Post# 36025414

RE:Adstiladrin Five Year Data Is Out

RE:Adstiladrin Five Year Data Is OutGreat share Eog.

That boggles the mind. That many instillations to 107 patients and only 6 get to be considered home free of the cancer.

Reading in more detail (although I find it confusing since two groupings)
107 CISTa/T1
50 CIS

3 month CR in CIS group was 55/107 =

After 4 treatments, if still good, were offered to continue getting instillations every 3m

42 patients kept going past a year it seems based on 26.5% recieving 5 or more instillations. So that means that the 12 m CR was 26.7% likely. Ruvidar beats that easily.

12 patients kept getting treatments to 57 months which is 19 instillations or more. So that is 12 patients out of 157 that were still CR towards the end of the whole stretch.

So start with 157
After 12 months down to 42
After 5 years, down to 12

If TLT can get the data out about whether the 450 day CRs stay CR further out, that would be an amazing contrast with this kind of never-ending instillation therapy.

<< Previous
Bullboard Posts
Next >>